Safety and Efficacy of GMX1777 in the Treatment of Refractory Solid Tumors or Lymphomas
Phase 1
Withdrawn
- Conditions
- Solid Tumors and Lymphomas
- Registration Number
- NCT00457574
- Lead Sponsor
- Gemin X
- Brief Summary
GMX1777 is a water-soluble, intravenously-administered prodrug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
- Detailed Description
This is a single-center, open-label, Phase I study of single-agent GMX1777 administered every 3 weeks to patients with CLL, MM, refractory solid tumors or lymphomas. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Patients must have a histologically or cytologically confirmed solid tumor or lymphoma
- No limitations on allowable type and amount of prior therapy.
- Patients must have a life expectancy of greater than 8 weeks
- Patients must have normal organ and marrow function
- Patients must be willing to submit blood sampling for planned PK analysis
- Patients must have the ability to understand and willingness to sign a written informed consent form
Exclusion Criteria
- No other agents or therapies administered with the intent to treat malignancy
- Patients with prior exposure to GMX1777 or GMX1778
- Uncontrolled, intercurrent illness
- Pregnant women and women who are breast feeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Determine the recommended Phase II dose; Characterize the dose-limiting toxicities; Determine the pharmacokinetic parameters 52 weeks
- Secondary Outcome Measures
Name Time Method Describe observed tumor responses 52 weeks